PRQR
PRQR clinical trials: ProQR Therapeutics N.V.
Every trial on ClinicalTrials.gov where ProQR Therapeutics N.V. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PRQR on the catalyst calendar · PRQR registry changes
- Primary completion Apr 12, 2022ActualPhase 1NCT05052554Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3ProQR Therapeutics · Fuchs Endothelial Corneal DystrophyWithdrawnPRQRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 7, 2022Sponsor estimatePhase 1/Phase 2NCT04123626A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H...ProQR Therapeutics · Autosomal Dominant Retinitis PigmentosaActive, not recruitingPRQRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 14, 2021ActualPhase 1/Phase 2NCT03780257Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A GeneProQR Therapeutics · Retinitis PigmentosaCompletedPRQRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2023Sponsor estimatePhase 2/Phase 3NCT04855045An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in...ProQR Therapeutics · Leber Congenital Amaurosis 10Unknown statusPRQRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2022ActualPhase 2/Phase 3NCT03913143A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)ProQR Therapeutics · Leber Congenital Amaurosis 10Active, not recruitingPRQRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2016ActualPhase 1NCT02564354Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR MutationProQR Therapeutics · Cystic FibrosisCompletedPRQRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 14, 2017ActualPhase 1/Phase 2NCT02532764Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis PatientsProQR Therapeutics · Cystic FibrosisCompletedPRQRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner